Cellectis reports Q3 adjusted EPS 2c vs (22c) last year

Reports Q3 revenue $35.17M vs 16.2M last year. “We are proud of the promising data from our core clinical product candidates. Our lasme-cel program for r/r B-ALL and eti-cel program for r/r NHL demonstrated their ability to induce deep and meaningful responses, underscoring their potential to improve outcomes in diseases with high unmet medical needs” said Andre Choulika, Ph.D., Chief Executive Officer at Cellectis (CLLS). “We look forward to sharing an additional development update on eti-cel at the ASH 2025 Annual Meeting and to provide the first interim analysis for the pivotal Phase 2 BALLI-01 trial in Q4 2026. Together, these milestones strengthen our leadership in allogeneic CAR-T innovation and position Cellectis for a transformative year ahead.”